Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor

MLA

Dirk Roymans, et al. “Therapeutic Efficacy of a Respiratory Syncytial Virus Fusion Inhibitor.” Nature Communications, vol. 8, no. 1, Aug. 2017, pp. 1–15. EBSCOhost, https://doi.org/10.1038/s41467-017-00170-x.

APA

Dirk Roymans, Sarhad S Alnajjar, Michael B Battles, Panchan Sitthicharoenchai, Polina Furmanova-Hollenstein, Peter Rigaux, Joke Van den Berg, Leen Kwanten, Marcia Van Ginderen, Nick Verheyen, Luc Vranckx, Steffen Jaensch, Eric Arnoult, Richard Voorzaat, Jack M. Gallup, Alejandro Larios-Mora, Marjolein Crabbe, Dymphy Huntjens, Pierre Raboisson, … Anil Koul. (2017). Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nature Communications, 8(1), 1–15. https://doi.org/10.1038/s41467-017-00170-x

Chicago

Dirk Roymans, Sarhad S Alnajjar, Michael B Battles, Panchan Sitthicharoenchai, Polina Furmanova-Hollenstein, Peter Rigaux, Joke Van den Berg, et al. 2017. “Therapeutic Efficacy of a Respiratory Syncytial Virus Fusion Inhibitor.” Nature Communications 8 (1): 1–15. doi:10.1038/s41467-017-00170-x.